✦ LIBER ✦

Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties

✍ Scribed by Serge Witchitz; Alain Cohen-Solal; Nathalie Dartois; Nadine Weisslinger; Karine Juste; Jean Yves Darmon

Book ID: 113973905
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 74 KB
Volume: 85
Category: Article
ISSN: 0002-9149
DOI: 10.1016/s0002-9149(00)00796-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of heart failure with ACE inhi

Treatment of heart failure with ACE inhibitors and beta-blockers

✍ Iwan C. C. van der Horst; Adriaan A. Voors; Dirk J. van Veldhuisen 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 160 KB

Treatment of heart failure with ACE inhi

Treatment of heart failure with ACE inhibitors and beta-blockers

✍ Uta C. Hoppe 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 158 KB

Treatment of heart failure with beta-blo

Treatment of heart failure with beta-blockers. Mechanisms and results

✍ M. Böhm; C. Maack 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 214 KB

Beta blocker treatment of heart failure

Beta blocker treatment of heart failure patients with ongoing cocaine use

✍ Littmann, Laszlo; Narveson, Sara Y.; Fesel, Nicole M.; Marconi, Sarah L. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 88 KB

A Comparison of Two Cardioselective Beta

A Comparison of Two Cardioselective Beta-Blockers with Different Ancillary Properties in the Treatment of Hypertension

✍ Mänttäri, M. ;Eisalo, A. 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 283 KB

Evaluation of celiprolol, a new cardiose

Evaluation of celiprolol, a new cardioselective beta1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly

✍ K. D. Lamon 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 499 KB

Celiprolol hydrochloride is a cardioselective beta 1-adrenergic antagonist with partial agonist activity. The studies discussed were designed to assess celiprolol's pharmacokinetic disposition, its efficacy versus placebo and other beta blockers, its relative safety profile, and its therapeutic rati